Biomarker ID | 1340 |
PMID | 24563673 |
Year | 2014 |
Biomarker | miR-1825 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Urine |
Subjects | Humans |
Regulation | Downregulated in PCa vs BPH vs Healthy |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathway Include: synapse; Golgi apparatus; cell junction; DNA-binding transcription factor activity; DNA-binding transcription factor activity, RNA polymerase II-specific |
Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 8 PCa patients, 12 BPH patients and 10 healthy males were selected for analysis |
Senstivity | 60% |
Specificity | 69% |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.01 |
Method Used | RT-qPCR |
Clinical | No |
Remarks | patients with a positive clinical diagnosis and exhibiting deregulation of either miR-1825 or miR-484 or deregulation of both were considered true positives; patients with a positive diagnosis and not exhibiting deregulation of any of the miRNAs (either separately or in tandem) were onsidered false negatives; patients with a negative diagnosis and exhibiting deregulation of either miR-1825, miR-484 or deregulation of both were con- sidered false positives; and finally, patients with a negative diagnosis and not exhibiting deregulation of either miR-1825 or miR-1825 or deregulation of both, were considered true negatives. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |